Methotrexate, a potent inhibitor of the ubiquitously expressed enzyme dihydrofolate reductase, induces limb and facial anomalies that resemble vascular disruptions in their evolution and final outcome. Previous studies suggest that inhibition of dihydrofolate reductase is responsible for methotrexate-induced embryopathy, although specific sites of methotrexate activity have not been well defined. In this report, we show that constitutive expression of a methotrexate-resistant form of dihydrofolate reductase in transgenic embryos and their placentas ameliorates methotrexate teratogenicity. However, expression of the transgene in maternal tissues had no significant protective effect. The results confirm the role of dihydrofolate reductase inhibition in the pathogenesis of methotrexate-induced birth defects and provide a foundation for future studies of targeted transgene expression in select embryonic or placental cell populations.
HuennekensFM. The methotrexate story: a paradigm for development of cancer chemotherapeutic agents. Adv Enzyme Regul1994;34:397–419.
2.
ChabnerBA, AllegraCJ, CurtGA, CalabresiP.Antineoplastic agents. In: GoodmanGilman, eds. The Pharmacological Basis of Therapeutics, 9th ed. New York: MacMillan, 1996;1243–1247.
3.
WiseCM, VuyyuruS, RobertsWN. Methotrexate in nonrenal lupus and undifferentiated connective tissue disease—a review of 36 patients. J Rheumatol1996;23:1005–1010.
4.
GansaugeS, BreitbartA, RinaldiN, Schwarz-EywillM.Methotrexate in patients with moderate systemic lupus erythematosis. Ann Rheum Dis1997;55:382–385.
5.
DayanM, SegalR, MozesE.Cytokine manipulation by methotrexate treatment in murine experimental systemic lupus erythematosis. J Rheumatol1997;24:1075–1082.
6.
SkalkoRG, GoldMP. Teratogenicity of methotrexate in mice. Teratology1974;9:159–164.
7.
HausknechtRV. Methotrexate and misoprostol to terminate early pregnancy. N Engl J Med1995;333:537–540.
8.
GrimesDA. Medical abortion in early pregnancy: a review of the evidence. Obstet Gynecol1997;89:790–796.
9.
FeldkampM, CareyJC. Clinical teratology counseling and consultation case report: low dose methotrexated exposure in the early weeks of pregnancy. Teratology1993;47:533–539.
10.
DonnenfeldAE, PastuszakA, SalkoffNJ, SchickB, RoseNC, KorenG.Methotrexate exposure prior to and during pregnancy. Teratology1994;49:79–81.
11.
KozlowskiRD, SteinbrunnerJV, MacKenzieAH, CloughJD, WilkeWS, SegalAM. Outcome of first-trimester exposure to low-dose methotrexate in eight patients with rheumatic disease. Am J Med1990;88:589–592.
WarkanyJ.Aminopterin and methotrexate: folic acid deficiency. Teratology1978;17:353–358.
14.
AvilesA, Diaz-MaqueoJC, TalaveraA, GuzmanR, GarciaEL. Growth and development of children of mothers treated with chemotherapy during pregnancy: current status of 43 patients. Am J Hematol1991;36:243–248.
BerryCL. Transient inhibition of DNA synthesis by methotrexate in the rat embryo and fetus. J Embryol Exp Morphol1971;26:469–474.
17.
DeSessoJM, JordanRL. Drug-induced limb dysplasias in fetal rabbits. Teratology1977;15:199–212.
18.
DeSessoJM, GoeringerGC. Amelioration by leucovorin of methotrexate developmental toxicity in rabbits. Teratology1991;43:201–205.
19.
DeSessoJM, GoeringerGC. Methotrexate-induced developmental toxicity in rabbits is ameliorated by 1-(p-tosyl)-3,4,4-trimethylimidazolidine, a functional analog for tetrahydrofolate-mediated one-carbon transfer. Teratology1992;45:271–283.
20.
DarabDJ, MinkoffR, ScioteJ, SulikKK. Pathogenesis of median facial clefts in mice treated with methotrexate. Teratology1987;36:77–86.
21.
JordanRL, WilsonJG, SchumacherHJ. Embryotoxicity of the folate antagonist methotrexate in rats and rabbits. Teratology1977;15:73–79.
FantelAG, BarberCV, MacklerB.Ischemia/reperfusion: a new hypothesis for the developmental toxicity of cocaine. Teratology1992;46:285–292.
24.
ChenC, Fen-fenL, Sheau-WenJ, Shuan-PeiL, Chung-ChiL.CVS exposed limb deficiency defects with or without other birth defects: presentation of 6 cases during a period of nine years. Am J Med Genet1996;63:447–453.
25.
LuijsterburgAJ, van-der-ZeeDC, GaillardJL, Chorionic villus sampling and end-artery disruption of the fetus. Prenat Diagn1997;17:71–76.
26.
SimonsenCC, LevinsonAD. Isolation and expression of an altered mouse dihydrofolate reductase cDNA. Proc Natl Acad Sci USA1983;80:2495–2499.
27.
HaberDA, BeverlySM, KielyML, SchimkeRT. Properties of an altered dihydrofolate reductase encoded by amplified genes in culture mouse fibroblasts. J Biol Chem1981;256:9501–9510.
28.
MorrisJA, MayC, KimHS, Comparative methotrexate resistance of transgenic mice expressing two distinct dihydrofolate reductase variants. Transgenics1996;2:53–67.
29.
MayC, GuntherR, McIvorRS. Protection of mice from lethal doses of methotrexate by transplantation with transgenic marrow expressing drug-resistant dihydrofolate reductase activity. Blood1995;86:2439–2448.
30.
IsolaLM, GordonJW. Systemic resistance to methotrexate in transgenic mice carrying a mutant dihydrofolate reductase gene. Proc Natl Acad Sci USA1986;83:9621–9625.
31.
MorrisJA, McIvorRS. Saturation mutagenesis at dihydrofolate reductase codons 22 and 31: a variety of amino acid substitutions conferring methotrexate-resistance. Biochem Pharmacol1994;47:1207–1220.
32.
JamesRI, MayC, VagtM, StudebakerR, McIvorRS. Transgenic mice expressing the tyr22 variant of murine DHFR: protection of transgenic marrow transplant recipients from lethal doses of methotrexate. Exp Hematol1997;25:1286–1295.
33.
BrentRL. Relationship between uterine vascular clamping, vascular disruption syndrome, and cocaine teratogenicity. Teratology1990;41:757–760.
34.
DanielssonBR, ReilandS, RundqvistE, DanielsonM.Digital defects induced by vasodilating agents: relationship to reduction in uteroplacental blood flow. Teratology1989; 40:351–358.
35.
Van AllenMI. Structural anomalies resulting from vascular disruption. Pediatr Clin North Am1992;39:255–277.
36.
MillicovskyG, DeSessoJM. Differential embryonic cardiovascular responses to acute maternal uterine ischemia: an in vivo microscopic study of rabbit embryos with either intact or clamped umbilical cords. Teratology1980;22:335–343.
37.
MillcovskyG, DeSessoJM, KleinmanLI, ClarkKE. Effects of hydroxyurea on hemodynamics of pregnant rabbits: a maternally mediated mechanism of embryotoxicity. Am J Obstet Gynecol140:747–781.
38.
PetterC, BourbonJ, MaltierJ-P, JostA.Simultaneous prevention of blood abnormalities and hereditary congenital amputations in a brachydactylous rabbit stock. Teratology1977;15:149–158.
39.
KapurRP, HoyleGW, MercerEH, BrinsterRL, PalmiterRD. Some neuronal cell populations express human dopamine phydroxylase-lacZ transgenes transiently during embryonic development. Neuron1991;7:717–727.
40.
JegalianBG, MillerRW, WrightCV, BlumM, De RobertisEM. A Hox 3.3-lacZ transgene expressed in developing limbs. MechDev1992;39:171–180.
41.
LiuY-H, MaL, WuL-Y, Regulation of the Msx2 homeobox gene during mouse embryogenesis: a transgene with 439 bp of f5' flanking sequence is expressed exclusively in the apical ectodermal ridge of the developing limb. Mech Dev1994;48:187–197.
42.
ShidaMM, Jackson-GrusbyLL, RossSR, LinzerDIH. Placental-specific expression from the mouse placental lacogen II gene promoter. Proc Natl Acad Sci USA1992;89:3864–3868.
43.
SabathDE, SpanglerEA, RubinEM, StamatoyannopoulosG.Analysis of the human zeta-globin gene promoter in transgenic mice. Blood1993;82:2899–2905.
